JPWO2019175222A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019175222A5 JPWO2019175222A5 JP2020547332A JP2020547332A JPWO2019175222A5 JP WO2019175222 A5 JPWO2019175222 A5 JP WO2019175222A5 JP 2020547332 A JP2020547332 A JP 2020547332A JP 2020547332 A JP2020547332 A JP 2020547332A JP WO2019175222 A5 JPWO2019175222 A5 JP WO2019175222A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acd25
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims 23
- 239000000427 antigen Substances 0.000 claims 22
- 102000036639 antigens Human genes 0.000 claims 22
- 108091007433 antigens Proteins 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 6
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 102000000588 Interleukin-2 Human genes 0.000 claims 4
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 3
- 229940124060 PD-1 antagonist Drugs 0.000 claims 2
- 230000009824 affinity maturation Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 206010039509 Scab Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642232P | 2018-03-13 | 2018-03-13 | |
| US201862642248P | 2018-03-13 | 2018-03-13 | |
| US201862642230P | 2018-03-13 | 2018-03-13 | |
| US201862642218P | 2018-03-13 | 2018-03-13 | |
| US201862642243P | 2018-03-13 | 2018-03-13 | |
| US62/642,232 | 2018-03-13 | ||
| PCT/EP2018/056312 WO2018167104A1 (en) | 2017-03-17 | 2018-03-13 | Fc-optimized anti-cd25 for tumour specific cell depletion |
| GBGB1804028.7A GB201804028D0 (en) | 2018-03-13 | 2018-03-13 | Anti-CD25 antibody agents |
| GBGB1804029.5A GB201804029D0 (en) | 2018-03-13 | 2018-03-13 | Anti-CD25 antibody agents |
| GB1804027.9 | 2018-03-13 | ||
| GBGB1804027.9A GB201804027D0 (en) | 2018-03-13 | 2018-03-13 | Anti-CD25 antibody agents |
| US62/642,218 | 2018-03-13 | ||
| US62/642,243 | 2018-03-13 | ||
| US62/642,248 | 2018-03-13 | ||
| US62/642,230 | 2018-03-13 | ||
| GB1804028.7 | 2018-03-13 | ||
| GB1804029.5 | 2018-03-13 | ||
| EPPCT/EP2018/056312 | 2018-03-13 | ||
| PCT/EP2019/056256 WO2019175222A1 (en) | 2018-03-13 | 2019-03-13 | Anti-cd25 for tumour specific cell depletion |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021516974A JP2021516974A (ja) | 2021-07-15 |
| JPWO2019175222A5 true JPWO2019175222A5 (hu) | 2022-03-18 |
| JP7565797B2 JP7565797B2 (ja) | 2024-10-11 |
Family
ID=67903878
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547333A Active JP7510348B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547371A Active JP7474701B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５抗体 |
| JP2020547363A Active JP7451414B2 (ja) | 2018-03-13 | 2019-03-13 | 抗ｃｄ２５抗体剤 |
| JP2020547331A Active JP7563979B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547332A Active JP7565797B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547326A Active JP7563978B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547415A Pending JP2021515568A (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547399A Active JP7451415B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547333A Active JP7510348B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547371A Active JP7474701B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５抗体 |
| JP2020547363A Active JP7451414B2 (ja) | 2018-03-13 | 2019-03-13 | 抗ｃｄ２５抗体剤 |
| JP2020547331A Active JP7563979B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547326A Active JP7563978B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547415A Pending JP2021515568A (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547399A Active JP7451415B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
Country Status (14)
| Country | Link |
|---|---|
| US (11) | US11697688B2 (hu) |
| EP (8) | EP3765503B1 (hu) |
| JP (8) | JP7510348B2 (hu) |
| KR (3) | KR20200131862A (hu) |
| CN (8) | CN112218891B (hu) |
| AU (3) | AU2019233576A1 (hu) |
| BR (3) | BR112020016519A2 (hu) |
| CA (3) | CA3088671A1 (hu) |
| CR (3) | CR20200467A (hu) |
| MA (1) | MA51993A (hu) |
| PE (3) | PE20210288A1 (hu) |
| SG (3) | SG11202008699WA (hu) |
| TW (3) | TW202003034A (hu) |
| WO (8) | WO2019175226A1 (hu) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017011592A1 (en) | 2015-07-13 | 2017-01-19 | Modular Genetics, Inc. | Generation of acyl alcohols |
| CN108795858A (zh) * | 2017-04-28 | 2018-11-13 | 深圳宾德生物技术有限公司 | 高抗癌活性t细胞的筛选方法和应用 |
| TW202003034A (zh) | 2018-03-13 | 2020-01-16 | 英商塔斯克療法有限公司 | 抗-cd25抗體藥劑 |
| CN114630838A (zh) * | 2019-05-20 | 2022-06-14 | 法国国家健康和医学研究院 | 新的抗cd25抗体 |
| TW202138388A (zh) | 2019-12-30 | 2021-10-16 | 美商西根公司 | 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法 |
| CN115397860A (zh) | 2020-05-14 | 2022-11-25 | 江苏恒瑞医药股份有限公司 | 抗cd25抗体、其抗原结合片段及其医药用途 |
| US11124568B1 (en) * | 2020-08-19 | 2021-09-21 | Vitruviae LLC | CD3/CD25 antibodies for neuro-immune diseases |
| CN116744962A (zh) * | 2020-11-13 | 2023-09-12 | 艾比欧公司 | Cd25抗体 |
| US20240002521A1 (en) * | 2020-11-20 | 2024-01-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd25 antibodies |
| EP4247497A1 (en) * | 2020-11-20 | 2023-09-27 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Anti-cd25 antibodies |
| EP4255929A2 (en) | 2020-12-02 | 2023-10-11 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| WO2022182483A1 (en) | 2021-02-02 | 2022-09-01 | Rakuten Medical, Inc. | Methods for local and systemic treatment of cancers, tumors and tumor cells |
| BR112023017638A2 (pt) | 2021-03-01 | 2023-10-10 | Hoffmann La Roche | Biomarcador, métodos para identificar um paciente com câncer e para tratar um paciente que sofre de câncer e agente anti-cd25 |
| WO2023016455A1 (zh) | 2021-08-09 | 2023-02-16 | 南京诺艾新生物技术有限公司 | 重组抗人cd25抗体及其应用 |
| CA3228786A1 (en) | 2021-08-25 | 2023-03-02 | Ibio, Inc. | Anti-cd25 antibody |
| US20240352136A1 (en) | 2021-09-02 | 2024-10-24 | Hoffmann-La Roche Inc. | Antibodies for the treatment of aml |
| CA3230426A1 (en) * | 2021-09-03 | 2023-03-09 | Novarock Biotherapeutics, Ltd. | Bispecific binding proteins that bind cd137 and a tumor associated antigen |
| CN118541391A (zh) | 2022-01-17 | 2024-08-23 | 诺纳生物（苏州）有限公司 | 靶向cd25的抗体及其制备方法和应用 |
| WO2023208990A1 (en) | 2022-04-26 | 2023-11-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist, |
| CN115197321B (zh) * | 2022-06-02 | 2023-08-18 | 四川大学 | 靶向cd25的抗体及其用途 |
| CN115181182B (zh) * | 2022-06-13 | 2024-03-29 | 南京融捷康生物科技有限公司 | 一种人源化的抗cd25的单域抗体及其应用 |
| CN115181181B (zh) * | 2022-06-13 | 2024-03-29 | 南京融捷康生物科技有限公司 | 一种抗cd25的单域抗体及其应用 |
| WO2024006965A1 (en) * | 2022-06-30 | 2024-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cd25-specific antibodies and uses thereof |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| CN118240080A (zh) * | 2022-12-22 | 2024-06-25 | 深圳市福元生物科技有限公司 | 一种cd25单域抗体、人源化抗体、及制备方法 |
| CN116004636B (zh) * | 2023-01-10 | 2024-03-12 | 广西师范大学 | 一种不结合红细胞的差异化cd47核酸适体及其应用 |
| WO2024165454A1 (en) | 2023-02-06 | 2024-08-15 | F. Hoffmann-La Roche Ag | Combination therapy and uses thereof |
| WO2024192065A1 (en) * | 2023-03-14 | 2024-09-19 | Odyssey Therapeutics, Inc. | Anti-cd25 antigen-binding proteins and uses thereof |
| WO2024204629A1 (ja) * | 2023-03-29 | 2024-10-03 | 第一三共株式会社 | 抗ｃｄ２５抗体及び抗ｃｄ２５抗体－薬物コンジュゲート |
| WO2024213046A1 (en) * | 2023-04-11 | 2024-10-17 | Suzhou Transcenta Therapeutics Co., Ltd. | Anti-cd25 antibody and uses thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| US4578335A (en) * | 1984-05-21 | 1986-03-25 | Immunex Corporation | Interleukin 2 receptor |
| CA2505991C (en) | 2002-11-15 | 2018-02-27 | Genmab A/S | Human monoclonal antibodies against cd25 |
| WO2004063355A2 (en) | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
| WO2004074437A2 (en) | 2003-02-14 | 2004-09-02 | University Of Southern California | Compositions and methods for cancer immunotherapy |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| WO2006050172A2 (en) | 2004-10-29 | 2006-05-11 | University Of Southern California | Combination cancer immunotherapy with co-stimulatory molecules |
| GB0507696D0 (en) | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
| JP2009542592A (ja) | 2006-07-06 | 2009-12-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法 |
| CN104098699A (zh) | 2006-08-18 | 2014-10-15 | 诺华有限公司 | Prlr特异性抗体及其用途 |
| EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| RU2391401C2 (ru) | 2008-02-12 | 2010-06-10 | Общество с ограниченной ответственностью "Лаборатория клеточного мониторинга" | СПОСОБ ПОЛУЧЕНИЯ ПОПУЛЯЦИИ CD4+CD25+Foxp3+ Т-ЛИМФОЦИТОВ ЧЕЛОВЕКА ex vivo, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ |
| CA2742968C (en) | 2008-11-07 | 2020-06-09 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| KR101545914B1 (ko) | 2009-09-22 | 2015-08-20 | 프로바이오겐 아게 | 특수화된 글리칸 구조를 함유하는 분자의 생산 방법 |
| WO2011077245A2 (en) | 2009-12-23 | 2011-06-30 | Fondazione Centro San Raffaele Del Monte Tabor | Compositions |
| TWI513466B (zh) | 2010-01-20 | 2015-12-21 | Boehringer Ingelheim Int | 抗凝血劑解毒劑 |
| EP2378287A1 (en) * | 2010-04-15 | 2011-10-19 | TXCell | New method for isolating Tr1 cells |
| WO2012012759A2 (en) | 2010-07-22 | 2012-01-26 | The Regents Of The University Of California | Anti-tumor antigen antibodies and methods of use |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| BR112015023084A2 (pt) * | 2013-03-15 | 2017-11-21 | Abbvie Biotechnology Ltd | anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira procariota e eucariota, método para a produção de um anticorpo anti-cd25 ou fragmento ligante anti-cd25, e, uso de um anticorpo anti-cd25 monoclonal de um conjugado anticorpo-droga ou de uma composição farmacêutica |
| CA2904527A1 (en) | 2013-03-15 | 2014-09-18 | Abbvie Biotechnology Ltd. | Anti-cd25 antibodies and their uses |
| CA3093606A1 (en) * | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Heterodimeric proteins for induction of t cells |
| NZ714765A (en) * | 2013-06-06 | 2021-12-24 | Pf Medicament | Anti-c10orf54 antibodies and uses thereof |
| WO2015109212A1 (en) * | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| GB201403775D0 (en) * | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| MX2016017288A (es) | 2014-07-16 | 2017-06-27 | Genentech Inc | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer. |
| SG11201700496WA (en) * | 2014-07-22 | 2017-02-27 | Cb Therapeutics Inc | Anti-pd-1 antibodies |
| CN106687124B (zh) | 2014-08-07 | 2022-03-15 | 冈村春树 | 并用il-18与分子靶向抗体的癌治疗药 |
| US11147652B2 (en) | 2014-11-13 | 2021-10-19 | Align Technology, Inc. | Method for tracking, predicting, and proactively correcting malocclusion and related issues |
| EP3789402B1 (en) * | 2014-11-20 | 2022-07-13 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
| ES2807182T3 (es) * | 2014-11-21 | 2021-02-22 | Bristol Myers Squibb Co | Anticuerpos frente a CD73 y sus usos |
| BR112017013385A2 (pt) * | 2014-12-23 | 2018-02-06 | Bristol-Myers Squibb Company | anticorpos para tigit |
| PT3295951T (pt) | 2015-02-19 | 2020-07-21 | Compugen Ltd | Anticorpos anti-pvrig e métodos de utilização |
| AU2016236270B2 (en) * | 2015-03-23 | 2022-01-27 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Anti-CEACAM6 antibodies and uses thereof |
| US10138298B2 (en) * | 2015-10-23 | 2018-11-27 | The Regents Of The University Of California | Anti-IL-2 antibodies and compositions and uses thereof |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| CA3016187A1 (en) * | 2016-03-04 | 2017-09-08 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
| KR102068600B1 (ko) * | 2016-03-04 | 2020-01-21 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | Pdl-1 항체, 그 약학적 조성물 및 그 용도 |
| MX2018012319A (es) * | 2016-04-07 | 2019-06-06 | Cancer Research Tech Ltd | Anticuerpos biespecificos contra el receptor de fc gamma cd25 para la reduccion de celulas especificas de tumores. |
| CA3027121A1 (en) * | 2016-06-10 | 2017-12-14 | Regeneron Pharmaceuticals, Inc. | Anti-gitr antibodies and uses thereof |
| JP6831651B2 (ja) | 2016-07-04 | 2021-02-17 | 川崎重工業株式会社 | ワークの袋詰め装置 |
| AU2017359172A1 (en) | 2016-11-08 | 2019-05-16 | Delinia, Inc. | IL-2 variants for the treatment of autoimmune diseases |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| US11119165B2 (en) | 2017-06-28 | 2021-09-14 | North Carolina State University Office of Research Commercialization | Photonic band-gap resonator for magnetic resonance applications |
| CN111094346A (zh) | 2017-07-06 | 2020-05-01 | 塔斯克疗法有限公司 | 用于肿瘤特异性细胞消耗的化合物和方法 |
| TW202003034A (zh) | 2018-03-13 | 2020-01-16 | 英商塔斯克療法有限公司 | 抗-cd25抗體藥劑 |
| MX2020008770A (es) | 2018-03-13 | 2020-10-08 | Tusk Therapeutics Ltd | Agentes anticuerpos anti-cd25. |
| KR20200003558A (ko) | 2018-07-02 | 2020-01-10 | 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. | 용지 슬립을 방지하기 위한 급지장치 및 이를 포함하는 화상형성장치 |
| KR102080909B1 (ko) | 2018-07-06 | 2020-02-24 | 한국수력원자력 주식회사 | 원자로의 해체 시스템 |
-
2019
- 2019-03-13 TW TW108108467A patent/TW202003034A/zh unknown
- 2019-03-13 JP JP2020547333A patent/JP7510348B2/ja active Active
- 2019-03-13 SG SG11202008699WA patent/SG11202008699WA/en unknown
- 2019-03-13 BR BR112020016519-0A patent/BR112020016519A2/pt not_active Application Discontinuation
- 2019-03-13 TW TW108108451A patent/TW201938588A/zh unknown
- 2019-03-13 US US16/979,935 patent/US11697688B2/en active Active
- 2019-03-13 CN CN201980019257.2A patent/CN112218891B/zh active Active
- 2019-03-13 EP EP19709955.9A patent/EP3765503B1/en active Active
- 2019-03-13 KR KR1020207029229A patent/KR20200131862A/ko unknown
- 2019-03-13 EP EP19709957.5A patent/EP3765505B1/en active Active
- 2019-03-13 WO PCT/EP2019/056260 patent/WO2019175226A1/en unknown
- 2019-03-13 PE PE2020001299A patent/PE20210288A1/es unknown
- 2019-03-13 US US16/352,717 patent/US10745485B2/en active Active
- 2019-03-13 JP JP2020547371A patent/JP7474701B2/ja active Active
- 2019-03-13 WO PCT/EP2019/056256 patent/WO2019175222A1/en active Application Filing
- 2019-03-13 JP JP2020547363A patent/JP7451414B2/ja active Active
- 2019-03-13 WO PCT/EP2019/056248 patent/WO2019175216A1/en active Application Filing
- 2019-03-13 AU AU2019233576A patent/AU2019233576A1/en not_active Abandoned
- 2019-03-13 CN CN201980019247.9A patent/CN112020513B/zh active Active
- 2019-03-13 CR CR20200467A patent/CR20200467A/es unknown
- 2019-03-13 WO PCT/EP2019/056252 patent/WO2019175220A1/en unknown
- 2019-03-13 JP JP2020547331A patent/JP7563979B2/ja active Active
- 2019-03-13 CN CN201980019256.8A patent/CN112020516A/zh active Pending
- 2019-03-13 CN CN201980019241.1A patent/CN112020512A/zh active Pending
- 2019-03-13 JP JP2020547332A patent/JP7565797B2/ja active Active
- 2019-03-13 TW TW108108452A patent/TW201940515A/zh unknown
- 2019-03-13 KR KR1020207029205A patent/KR20200131286A/ko unknown
- 2019-03-13 CA CA3088671A patent/CA3088671A1/en active Pending
- 2019-03-13 EP EP19709956.7A patent/EP3765504B1/en active Active
- 2019-03-13 JP JP2020547326A patent/JP7563978B2/ja active Active
- 2019-03-13 WO PCT/EP2019/056249 patent/WO2019175217A1/en active Application Filing
- 2019-03-13 WO PCT/EP2019/056247 patent/WO2019175215A1/en unknown
- 2019-03-13 BR BR112020016499-2A patent/BR112020016499A2/pt not_active Application Discontinuation
- 2019-03-13 EP EP19709958.3A patent/EP3765506B1/en active Active
- 2019-03-13 US US16/979,929 patent/US11802161B2/en active Active
- 2019-03-13 EP EP19711075.2A patent/EP3765510A1/en active Pending
- 2019-03-13 AU AU2019233575A patent/AU2019233575A1/en not_active Abandoned
- 2019-03-13 BR BR112020016501-8A patent/BR112020016501A2/pt unknown
- 2019-03-13 SG SG11202008784RA patent/SG11202008784RA/en unknown
- 2019-03-13 CA CA3088659A patent/CA3088659A1/en not_active Abandoned
- 2019-03-13 CR CR20200466A patent/CR20200466A/es unknown
- 2019-03-13 EP EP19709954.2A patent/EP3765502B1/en active Active
- 2019-03-13 CN CN201980019248.3A patent/CN112020514B/zh active Active
- 2019-03-13 KR KR1020207029221A patent/KR20200131861A/ko not_active Application Discontinuation
- 2019-03-13 US US16/979,933 patent/US11919960B2/en active Active
- 2019-03-13 WO PCT/EP2019/056257 patent/WO2019175223A1/en unknown
- 2019-03-13 US US16/979,932 patent/US11873341B2/en active Active
- 2019-03-13 PE PE2020001320A patent/PE20210289A1/es unknown
- 2019-03-13 EP EP19711315.2A patent/EP3765511B1/en active Active
- 2019-03-13 JP JP2020547415A patent/JP2021515568A/ja active Pending
- 2019-03-13 JP JP2020547399A patent/JP7451415B2/ja active Active
- 2019-03-13 US US16/979,930 patent/US11814434B2/en active Active
- 2019-03-13 US US16/352,703 patent/US10738125B2/en active Active
- 2019-03-13 WO PCT/EP2019/056258 patent/WO2019175224A1/en unknown
- 2019-03-13 CA CA3088246A patent/CA3088246A1/en not_active Abandoned
- 2019-03-13 PE PE2020001292A patent/PE20210287A1/es unknown
- 2019-03-13 CN CN201980019234.1A patent/CN112074536B/zh active Active
- 2019-03-13 MA MA051993A patent/MA51993A/fr unknown
- 2019-03-13 US US16/352,709 patent/US10752691B2/en active Active
- 2019-03-13 AU AU2019233581A patent/AU2019233581A1/en active Pending
- 2019-03-13 CN CN201980019249.8A patent/CN112020515B/zh active Active
- 2019-03-13 CN CN201980019235.6A patent/CN112041345A/zh active Pending
- 2019-03-13 US US16/979,931 patent/US11851494B2/en active Active
- 2019-03-13 EP EP19710416.9A patent/EP3765507B1/en active Active
- 2019-03-13 SG SG11202008733YA patent/SG11202008733YA/en unknown
- 2019-03-13 CR CR20200465A patent/CR20200465A/es unknown
-
2020
- 2020-02-05 US US16/782,461 patent/US11787866B2/en active Active
- 2020-02-05 US US16/782,440 patent/US11802160B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019175222A5 (hu) | ||
| JPWO2019175217A5 (hu) | ||
| JPWO2019175220A5 (hu) | ||
| JPWO2019175216A5 (hu) | ||
| JPWO2019175215A5 (hu) | ||
| JPWO2019175226A5 (hu) | ||
| US20210024635A1 (en) | Anti-wt1/hla-specific antibodies | |
| JPWO2019175224A5 (hu) | ||
| JPWO2019175223A5 (hu) | ||
| Wang et al. | Development of therapeutic antibodies for the treatment of diseases | |
| JP7254699B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| US11427642B2 (en) | Anti-BCMA heavy chain-only antibodies | |
| US20210188989A1 (en) | Anti-4-1bb antibodies and methods of making and using thereof | |
| JP2018510636A5 (hu) | ||
| CA3067584A1 (en) | Anti-bcma heavy chain-only antibodies | |
| JP2020521504A (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| JP2020522280A5 (hu) | ||
| JP2020522281A5 (hu) | ||
| JP2020533965A5 (hu) | ||
| IL265762B1 (en) | Dosing regimen of avolumab for cancer treatment | |
| JP2020531003A5 (hu) | ||
| RU2020128108A (ru) | Антитело против cd25 для опухоль-специфической клеточной деплеции | |
| US20240067741A1 (en) | Anti-4-1bb antibodies and methods of making and using thereof | |
| EP4114373A1 (en) | Anti-cd19 antibodies and methods of using and making thereof | |
| CN115335402A (zh) | 特异性抗原结合分子,其制备方法及医药用途 |